High-dose IV ascorbic acid therapy in CCUS patients with TET2 mutations

Xie, Zhuoer; Fernandez, Jenna; Lasho, Terra L; Finke, Christy M.; Amundson, Michelle; McCullough, Kristen; LaPlant, Betsy; Mangaonkar, Abhishek A; Gangat, Naseema; Reichard, Kaaren K; Elliott, Michelle Ann; Witzig, Thomas E.; Patnaik, Mrinal M.

doi:10.1182/blood.2024024962

This was a phase II trial, evaluating the safety/efficacy of high-dose IV-ascorbic acid in patients with TET2 mutant CCUS. Eight of 10 patients enrolled were eligible for response assessment. At week 20, there were no responses by IWG MDS criteria. NCT03418038

This content is only available as a PDF.

2024

Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Sign in via your Institution

High-dose IV ascorbic acid therapy in CCUS patients with TET2 mutations

Article PDF first page preview

Supplemental data

Cited By

Email alerts

ASH Publications

American Society of Hematology

High-dose IV ascorbic acid therapy in CCUS patients with TET2 mutations

Article PDF first page preview

Supplemental data

This feature is available to Subscribers Only

My Account

Cited By

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only